SCHEMBL1408800

SCHEMBL1408800

[NH]S(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ NT5E P21589 1/20 0.64
▸ LMNA P02545 2/20 0.62
▸ HTR6 P50406 2/20 0.62
▸ MPO P05164 1/20 0.62
▸ CYP3A4 P08684 1/20 0.62
▸ CYP2C9 P11712 1/20 0.62
▸ CA2 P00918 4/20 0.59
▸ CA9 Q16790 4/20 0.59
▸ CA1 P00915 3/20 0.59
▸ CA12 O43570 3/20 0.59
▸ CA14 Q9ULX7 2/20 0.59
▸ AGO2 Q9UKV8 2/20 0.59
▸ TDP1 Q9NUW8 2/20 0.59
▸ USP2 O75604 1/20 0.59
▸ CA4 P22748 1/20 0.59
▸ CA6 P23280 1/20 0.59
▸ CA5A P35218 1/20 0.59
▸ CA7 P43166 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30495973 0.78 TSHR (1.00) TSHRALDH1A1NT5ELMNAHTR6
SCHEMBL31415204 0.78 TSHR (1.00) TSHRALDH1A1NT5ELMNAHTR6
SCHEMBL482994 0.78 TSHR (1.00) TSHRALDH1A1NT5ELMNAHTR6
SCHEMBL24407 0.78 TSHR (1.00) TSHRALDH1A1NT5ELMNAHTR6
Dapsone SCHEMBL5055312 0.77 HTR6 (1.00) TSHRALDH1A1NT5ELMNAHTR6
SCHEMBL324893 0.77 HTR6 (1.00) TSHRALDH1A1NT5ELMNAHTR6
SCHEMBL10596934 0.77 HTR6 (1.00) TSHRALDH1A1NT5ELMNAHTR6
Dapsone SCHEMBL1219599 0.77 HTR6 (1.00) TSHRALDH1A1NT5ELMNAHTR6
Dapsone SCHEMBL21428 0.77 HTR6 (1.00) TSHRALDH1A1NT5ELMNAHTR6
Sulfuric Acid SCHEMBL10596856 0.76 TSHR (0.95) TSHRALDH1A1NT5ELMNAHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4261217-A9 COMPOUND FOR RNA CAPPING AND APPLICATION OF COMPOUND Guangzhou Henovcom Bioscience Co., Ltd. (CN) 2023-12-27 — — EP claimed
EP-4261217-A1 COMPOUND FOR RNA CAPPING AND APPLICATION OF COMPOUND Guangzhou Henovcom Bioscience Co., Ltd. (CN) 2023-10-18 — — EP claimed
US-10710993-B2 Benzofuran pyrazole amine kinase inhibitor Hangzhou REX Pharmaceutical Co., LTD. (CN) 2020-07-14 — — US claimed
US-20190225600-A1 BENZOFURAN PYRAZOLE AMINE KINASE INHIBITOR Hangzhou REX Pharmaceutical Co., LTD. (CN) 2019-07-25 — — US claimed
EP-3476848-A1 BENZOFURAN PYRAZOLE AMINE PROTEIN KINASE INHIBITOR Hangzhou Rex Pharmaceutical Co., Ltd (CN) 2019-05-01 — — EP claimed
EP-2496628-A1 METHOD FOR PRODUCING AN AQUEOUS POLYMER DISPERSION BASF SE (DE) 2012-09-12 — — EP claimed
US-20120208959-A1 METHOD FOR PRODUCING AN AQUEOUS POLYMER DISPERSION BASF SE (DE) 2012-08-16 — — US claimed
WO-2011051374-A1 METHOD FOR PRODUCING AN AQUEOUS POLYMER DISPERSION BASF SE (DE) 2011-05-05 — — WO claimed
CN-101821243-A Pyrimidine substituted phenylpropionic acid derivatives and application thereof as PPAR (peroxisome proliferator activated receptor) agonist CHANGZHEN HOSPITAL SHANGHAI 2010-09-01 — — CN claimed
EP-1283042-B1 AQUEOUS LIQUID PREPARATION OF PRANOPROFEN SENJU PHARMA CO (JP) 2008-10-08 — — EP claimed
US-4990523-A Treatment of chronic inflammatory joint disease with arylsulfonamides A. H. ROBINS COMPANY, INCORPORATED (US) 1991-02-05 — — US claimed
WO-1990015600-A2 TREATMENT OF CHRONIC INFLAMMATORY JOINT DISEASE WITH ARYLSULFONAMIDES A.H. ROBINS COMPANY, INCORPORATED (US) 1990-12-27 — — WO claimed
US-4876252-A ADMINISTERING ANTIASTHMATIC OR ANTIALLERGEN AMERICAN CYANAMID COMPANY (US) 1989-10-24 — — US claimed
US-4788195-A TREATING ASTHMA, ALLERGIC DISEASES, INFLAMMATION AND DIABETES IN MAMMALS AMERICAN CYANAMID COMPANY (US) 1988-11-29 — — US claimed
EP-0233461-A2 4,5,6-Substituted-2-pyrimidinamines AMERICAN CYANAMID COMPANY (US) 1987-08-26 — — EP claimed
US-4464366-A Cephem compounds having a terminal aminocarboxylic acid grouping and containing an azacyclyl(thio)ureido group CIBA GEIGY CORPORATION (US) 1984-08-07 — — US claimed
US-4374134-A Cephalosporin compounds with terminal aminocarboxylic acid groupings and anti-bacterial use thereof CIBA-GEIGY CORPORATION (US) 1983-02-15 — — US claimed
US-4061751-A 6-Substituted 3-nitroimidazo[1,2-b]pyridazine for the control of foot rot and liver lesions in ruminant animals AMERICAN CYANAMID COMPANY (US) 1977-12-06 — — US claimed
US-4060614-A 6-Substituted 3-nitroimidazo[1,2-b]pyridazine for the control of hemorrhagic colitis in swine AMERICAN CYANAMID COMPANY (US) 1977-11-29 — — US claimed
US-3975399-A PROSTAGLANDIN LIKE ACTIVITY E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-08-17 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10710993-B2 Benzofuran pyrazole amine kinase inhibitor ALK, MAP3K5, ARAF TSHR 3699/4885ALDH1A1 1248/4885NT5E 3457/4885
US-20190225600-A1 BENZOFURAN PYRAZOLE AMINE KINASE INHIBITOR ALK, MAP3K5, ARAF TSHR 3699/4885ALDH1A1 1248/4885NT5E 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback